2025
Comparative Risk of Adverse Pancreatic Events with GLP-1 Receptor Agonists, SGLT2 Inhibitors, DPP4 Inhibitors, and Sulfonylureas among Adults with Type 2 Diabetes at Moderate Cardiovascular Disease Risk
Kalathiya U, Herrin J, Swarna K, Deng Y, Polley E, Neumiller J, Galindo R, Umpierrez G, Ross J, Mickelson M, McCoy R. Comparative Risk of Adverse Pancreatic Events with GLP-1 Receptor Agonists, SGLT2 Inhibitors, DPP4 Inhibitors, and Sulfonylureas among Adults with Type 2 Diabetes at Moderate Cardiovascular Disease Risk. Endocrine Practice 2025 PMID: 40945659, DOI: 10.1016/j.eprac.2025.09.004.Peer-Reviewed Original ResearchSodium-glucose cotransporter 2 inhibitorsDipeptidyl peptidase-4 inhibitorsRisk of acute pancreatitisAssociated with lower riskGLP-1RAAcute pancreatitisPancreatic cancerType 2 diabetesPancreatitis eventsReceptor agonistsDipeptidyl peptidase-4 inhibitor therapyGlucagon-like peptide-1 receptor agonistsRisk of pancreatic cancerLow riskFee-for-service MedicarePeptide-1 receptor agonistsGLP-1 receptor agonistsIncident acute pancreatitisModerate cardiovascular disease riskDe-identified claims dataComparative riskAcute pancreatitis riskAssociated with higher riskInverse probabilityPeptidase-4 inhibitors308-OR: Risk of New Cancer Diagnoses with GLP-1 Receptor Agonist, SGLT2 Inhibitor, DPP-4 Inhibitor, and Sulfonylurea Use in Type 2 Diabetes
SKLEPINSKI S, HERRIN J, SINDHU SWARNA K, NEUMILLER J, GALINDO R, UMPIERREZ G, ROSS J, DENG Y, POLLEY E, MICKELSON M, MCCOY R. 308-OR: Risk of New Cancer Diagnoses with GLP-1 Receptor Agonist, SGLT2 Inhibitor, DPP-4 Inhibitor, and Sulfonylurea Use in Type 2 Diabetes. Diabetes 2025, 74 DOI: 10.2337/db25-308-or.Peer-Reviewed Original ResearchDipeptidyl peptidase-4 inhibitorsIncident cancer riskSodium-glucose cotransporter 2 inhibitorsIncident cancerGLP-1RACancer riskHigher risk of incident cancerType 2 diabetesRisk of incident cancerHigh riskReceptor agonistsMedicare fee-for-serviceFemale breast cancerFee-for-serviceGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsGLP-1 receptor agonistsPropensity score inverse probabilityTarget trial emulationModerate CVD riskCox proportional hazards modelsOptumLabs Data WarehousePeptidase-4 inhibitorsIncidence of melanomaAdverse cardiovascular events780-P: Comparative Risk of Adverse Pancreatic Events with Second-Line Glucose-Lowering Therapies in Adults with Type 2 Diabetes at Moderate Cardiovascular Disease Risk
KALATHIYA U, HERRIN J, SINDHU SWARNA K, NEUMILLER J, GALINDO R, UMPIERREZ G, ROSS J, DENG Y, POLLEY E, MICKELSON M, MCCOY R. 780-P: Comparative Risk of Adverse Pancreatic Events with Second-Line Glucose-Lowering Therapies in Adults with Type 2 Diabetes at Moderate Cardiovascular Disease Risk. Diabetes 2025, 74 DOI: 10.2337/db25-780-p.Peer-Reviewed Original ResearchSodium-glucose cotransporter 2 inhibitorsGLP-1RAAcute pancreatitisPancreatic cancerType 2 diabetesRisk of pancreatic cancerIncident acute pancreatitisMedicare fee-for-servicePancreatitis eventsComparative riskAssociated with lower riskFee-for-serviceCardiovascular disease riskGlucagon-like peptide-1 receptor agonistsModerate cardiovascular disease riskSecond-line glucose-lowering therapyAssociated with increased riskAssociated with higher riskRisk of acute pancreatitisPeptide-1 receptor agonistsPropensity score inverse probabilityDipeptidyl peptidase-4 inhibitorsOptumLabs Data WarehouseGLP-1RA therapyModerate cardiovascular riskRisk of Thyroid Tumors With GLP-1 Receptor Agonists: A Retrospective Cohort Study
Morales D, Bu F, Viernes B, DuVall S, Matheny M, Simon K, Falconer T, Richter L, Ostropolets A, Lau W, Man K, Chattopadhyay S, Mathioudakis N, Minty E, Nishimura A, Sun F, Yin C, Seager S, Chai Y, Zhou J, Lu Y, Reyes C, Pistillo A, Duarte-Salles T, Blacketer C, Schuemie M, Ryan P, Krumholz H, Hripcsak G, Khera R, Suchard M. Risk of Thyroid Tumors With GLP-1 Receptor Agonists: A Retrospective Cohort Study. Diabetes Care 2025, 48: 1386-1394. PMID: 40465422, PMCID: PMC12281980, DOI: 10.2337/dc25-0154.Peer-Reviewed Original ResearchRisk of thyroid tumorThyroid tumorsGLP-1RADPP-4isHazard ratioThyroid malignancyCohort studyIncreased riskSodium-glucose cotransporter 2 inhibitorsElectronic health record databaseGlucagon-like peptide 1 receptor agonistsEstimate hazard ratiosRandom-effects meta-analysisGLP-1 receptor agonistsPeptide 1 receptor agonistsDipeptidyl peptidase 4 inhibitorsThyroid tumor incidenceUsers of SGLT2isHealth record databaseSecond-line treatmentType 2 diabetes mellitusNew-user cohort studyRetrospective cohort studyUsers of sulfonylureasIntention-to-treatEffects of Tirzepatide in Type 2 Diabetes Individual Variation and Relationship to Cardiometabolic Outcomes
Aminorroaya A, Oikonomou E, Biswas D, Jastreboff A, Khera R. Effects of Tirzepatide in Type 2 Diabetes Individual Variation and Relationship to Cardiometabolic Outcomes. Journal Of The American College Of Cardiology 2025, 85: 1858-1872. PMID: 40368575, PMCID: PMC12186526, DOI: 10.1016/j.jacc.2025.03.516.Peer-Reviewed Original ResearchConceptsElevated body mass indexCardiometabolic abnormalitiesBody mass indexOdds of elevated body mass indexType 2 diabetesIndividual Participant Data Meta-AnalysisMass indexParticipant data meta-analysisOdds of MetSCardiometabolic risk factorsComponents of metabolic syndromeData Meta-AnalysisHigh-density lipoprotein cholesterolCardiometabolic healthStudy design differencesMixed-effects modelsBaseline usePhase 3 randomized clinical trialSodium-glucose cotransporter 2 inhibitorsOddsStudy outcomesEffects of tirzepatideMeta-analysisRisk factorsClinical subpopulationsAssociation of Endocrinologists on Clinical Care Team With Sodium-Glucose Cotransporter 2 Inhibitor Prescription for People With Type 2 Diabetes After Coronary Artery Bypass Grafting: A Two-Center Study.
Yi Y, Kumar N, Smith M, Mueller A, Houle T, Jassar A, Cornella L, Schonberger R, Bardia A. Association of Endocrinologists on Clinical Care Team With Sodium-Glucose Cotransporter 2 Inhibitor Prescription for People With Type 2 Diabetes After Coronary Artery Bypass Grafting: A Two-Center Study. Clinical Diabetes 2025, 43: 409-415. PMID: 40741469, PMCID: PMC12304554, DOI: 10.2337/cd24-0107.Peer-Reviewed Original ResearchSodium-glucose cotransporter 2Coronary Artery Bypass GraftingType 2 diabetesArtery Bypass GraftingInhibitor prescriptionBypass GraftingSodium-glucose cotransporter 2 inhibitorsTwo-center studyCotransporter 2Sodium-glucosePostoperative careEndocrinologistsClinical care teamTwo-centerPatientsTreatment teamPrescriptionGLP-1RA Use and Thyroid Cancer Risk
Brito J, Herrin J, Swarna K, Ospina N, Montori V, Toro-Tobon D, Umpierrez G, Galindo R, Deng Y, Mickelson M, Shao H, Polley E, McCoy R. GLP-1RA Use and Thyroid Cancer Risk. JAMA Otolaryngology - Head & Neck Surgery 2025, 151: 243-252. PMID: 39847346, PMCID: PMC11907303, DOI: 10.1001/jamaoto.2024.4852.Peer-Reviewed Original ResearchConceptsDipeptidyl peptidase-4 inhibitorsModified intention-to-treatSodium-glucose cotransporter 2 inhibitorsTarget trial emulationGLP-1RA initiationComparative effectiveness studiesGLP-1RAThyroid cancerType 2 diabetesSecondary analysisMedicare fee-for-service planTrial emulationHazard ratioAssociated with increased overall riskIncident thyroid cancerDipeptidyl peptidase-4 inhibitor groupTreated with GLP-1RAGlucagon-like peptide-1 receptor agonistsHistory of thyroid cancerFee-for-service plansModified intention-to-treat analysisPeptide-1 receptor agonistsEnhanced early detectionGLP-1RA therapyPeptidase-4 inhibitorsDiuretic Potentiation Strategies in Acute Heart Failure
Siddiqi T, Packer M, Ezekowitz J, Fonarow G, Greene S, Kittleson M, Khan M, Mentz R, Testani J, Voors A, Butler J. Diuretic Potentiation Strategies in Acute Heart Failure. JACC Heart Failure 2025, 13: 14-27. PMID: 39779178, DOI: 10.1016/j.jchf.2024.09.017.Peer-Reviewed Original ResearchConceptsAcute heart failureHeart failureReceptor antagonistSodium-glucose cotransporter 2 inhibitorsLoop diuretic agentsMarkers of congestionMineralocorticoid receptor antagonistsVasopressin receptor antagonistsHeart failure eventsLong-term outcomesShort-term markersCarbonic anhydrase inhibitorsDiuretic strategyThiazide diureticsSerum creatinineDecongestion strategiesClinical outcomesConventional therapyDiuretic agentsImprove symptomsPhysical signsDiureticsCombination strategiesSymptomsAntagonist
2024
Patients With Diabetes on Sodium-Glucose Cotransporter-2 Inhibitors Undergoing Total Knee Arthroplasty Are at Increased Odds for a Number of Postoperative Adverse Events But Reduced Risk of Transfusion
Kim L, Wiznia D, Grauer J. Patients With Diabetes on Sodium-Glucose Cotransporter-2 Inhibitors Undergoing Total Knee Arthroplasty Are at Increased Odds for a Number of Postoperative Adverse Events But Reduced Risk of Transfusion. Journal Of The American Academy Of Orthopaedic Surgeons 2024, 33: 856-862. PMID: 39630933, DOI: 10.5435/jaaos-d-24-00299.Peer-Reviewed Original ResearchSodium-glucose cotransporter 2 inhibitorsDM patientsAdverse eventsDiabetes mellitusTotal knee arthroplastySGLT2i useElixhauser Comorbidity IndexComorbidity indexMultivariate analysisIncidence of blood transfusionReduced risk of transfusionAssociated with multiple complicationsOdds of transfusionUrinary tract infectionAssociated with increased riskPerioperative adverse outcomesRisk of transfusionAssociated with reduced incidenceAcute kidney injuryPostoperative adverse eventsSurgical decision makingControlled DM patientsActive tobacco useGroup of medicationsAssociated with higher oddsRecent trends in GLP-1 RA and SGLT2i use among people with type 2 diabetes and atherosclerotic cardiovascular disease in the USA
King A, Tan X, Dhopeshwarkar N, Bohn R, Dea K, Leonard C, de Havenon A. Recent trends in GLP-1 RA and SGLT2i use among people with type 2 diabetes and atherosclerotic cardiovascular disease in the USA. BMJ Open Diabetes Research & Care 2024, 12: e004431. PMID: 39366717, PMCID: PMC11459310, DOI: 10.1136/bmjdrc-2024-004431.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2 inhibitorsGLP-1 RAsAtherosclerotic cardiovascular diseaseGLP-1Type 2 diabetesIncident useGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsCardiovascular diseasePrevalence of atherosclerotic cardiovascular diseaseASCVD diagnosisProportion of patientsRetrospective observational studyNested cohort studyReceptor agonistsSGLT2i useAnalysis of cross-sectional dataSodium-glucoseCohort studyPatient numbersObservational studyPatientsPrevalent useCross-sectional dataT2DFirst interim results from FINE-REAL: a prospective, non-interventional, phase 4 study providing insights into the use and safety of finerenone in a routine clinical setting
Nicholas S, Correa-Rotter R, Desai N, Guo L, Navaneethan S, Pantalone K, Wanner C, Hamacher S, Fatoba S, Horvat-Broecker A, Garreta-Rufas A, Gay A, Merz M, Wheeler D. First interim results from FINE-REAL: a prospective, non-interventional, phase 4 study providing insights into the use and safety of finerenone in a routine clinical setting. Journal Of Nephrology 2024, 37: 2223-2232. PMID: 39340711, PMCID: PMC11649709, DOI: 10.1007/s40620-024-02070-y.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseMedian Follow-UpNon-interventional study of patientsNon-steroidal mineralocorticoid receptor antagonistPrimary care settingMonths median follow-upTreatment-emergent adverse eventsSodium-glucose cotransporter 2 inhibitorsInterim analysisAngiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor BlockersCKD risk categoryAssociated with type 2 diabetesMineralocorticoid receptor antagonistsClinical practiceInhibitors/angiotensin receptor blockersPhase 4 studyNon-interventional studyStudy of patientsCare settingsRoutine careType 2 diabetesFinerenone treatmentTreatment discontinuationReceptor antagonistReceptor blockersRisk of Severe Hypoglycemia After Initiation of Noninsulin Glucose-Lowering Therapies in Adults With Type 2 Diabetes at Moderate Cardiovascular Disease Risk.
McCoy R, Swarna K, Neumiller J, Polley E, Deng Y, Mickelson M, Herrin J. Risk of Severe Hypoglycemia After Initiation of Noninsulin Glucose-Lowering Therapies in Adults With Type 2 Diabetes at Moderate Cardiovascular Disease Risk. Clinical Diabetes 2024, 43: 59-70. PMID: 39829688, PMCID: PMC11739335, DOI: 10.2337/cd24-0007.Peer-Reviewed Original ResearchSodium-glucose cotransporter 2Moderate cardiovascular disease riskRisk of severe hypoglycemiaGlucose-lowering therapyCardiovascular disease riskType 2 diabetesSevere hypoglycemiaSodium-glucose cotransporter 2 inhibitorsDPP-4GLP-1 receptor agonistsGlucagon-like peptide 1Risk of hypoglycemiaDPP-4 inhibitorsDipeptidyl peptidase 4Disease riskAvoidance of hypoglycemiaSulfonylurea therapyReceptor agonistsCotransporter 2Sulfonylurea usePatient populationGLP-1Peptidase 4HypoglycemiaEmergency departmentInpatient Use of Guideline-Directed Medical Therapy During Heart Failure Hospitalizations Among Community-Based Health Systems
Zheng J, Sandhu A, Bhatt A, Collins S, Flint K, Fonarow G, Fudim M, Greene S, Heidenreich P, Lala A, Testani J, Varshney A, Wi R, Ambrosy A. Inpatient Use of Guideline-Directed Medical Therapy During Heart Failure Hospitalizations Among Community-Based Health Systems. JACC Heart Failure 2024, 13: 43-54. PMID: 39269395, DOI: 10.1016/j.jchf.2024.08.004.Peer-Reviewed Original ResearchCommunity-based health systemQuality improvement registryHealth systemGuideline-directed medical therapyGuideline-directed medical therapy useEligible hospitalsImprovement registryNational quality improvement registryElectronic health record dataHealth record dataEvidence-based medicationsHF hospitalizationHeart failurePostdischarge strategiesHFrEF patientsFailure hospitalizationMedical therapyCommunity-BasedAngiotensin receptor-neprilysin inhibitorSodium-glucose cotransporter 2 inhibitorsInpatient useRecord dataRenin-angiotensin system inhibitorsMineralocorticoid receptor antagonistsWorsening Renal FunctionComparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes A Multinational, Federated Analysis of LEGEND-T2DM
Khera R, Aminorroaya A, Dhingra L, Thangaraj P, Pedroso Camargos A, Bu F, Ding X, Nishimura A, Anand T, Arshad F, Blacketer C, Chai Y, Chattopadhyay S, Cook M, Dorr D, Duarte-Salles T, DuVall S, Falconer T, French T, Hanchrow E, Kaur G, Lau W, Li J, Li K, Liu Y, Lu Y, Man K, Matheny M, Mathioudakis N, McLeggon J, McLemore M, Minty E, Morales D, Nagy P, Ostropolets A, Pistillo A, Phan T, Pratt N, Reyes C, Richter L, Ross J, Ruan E, Seager S, Simon K, Viernes B, Yang J, Yin C, You S, Zhou J, Ryan P, Schuemie M, Krumholz H, Hripcsak G, Suchard M. Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes A Multinational, Federated Analysis of LEGEND-T2DM. Journal Of The American College Of Cardiology 2024, 84: 904-917. PMID: 39197980, PMCID: PMC12045554, DOI: 10.1016/j.jacc.2024.05.069.Peer-Reviewed Original ResearchConceptsGLP-1 RAsSecond-line agentsGLP-1Antihyperglycemic agentsCardiovascular diseaseMACE riskGlucagon-like peptide-1 receptor agonistsSodium-glucose cotransporter 2 inhibitorsPeptide-1 receptor agonistsDipeptidyl peptidase-4 inhibitorsEffects of SGLT2isType 2 diabetes mellitusPeptidase-4 inhibitorsAdverse cardiovascular eventsCox proportional hazards modelsRandom-effects meta-analysisCardiovascular risk reductionTarget trial emulationProportional hazards modelPrescription Patterns for Sodium-Glucose Cotransporter 2 Inhibitors in U.S. Health Systems
Shin J, Xu Y, Chang A, Carrero J, Flaherty C, Mukhopadhyay A, Inker L, Blecker S, Horwitz L, Grams M. Prescription Patterns for Sodium-Glucose Cotransporter 2 Inhibitors in U.S. Health Systems. Journal Of The American College Of Cardiology 2024, 84: 683-693. PMID: 39142721, PMCID: PMC11789666, DOI: 10.1016/j.jacc.2024.05.057.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2Class 1A recommendationSodium-glucose cotransporter 2 inhibitor therapyChronic kidney diseaseU.S. health systemHealth systemInhibitor prescriptionHeart failurePrescription ratesInhibitor therapyInhibitor useSodium-glucose cotransporter 2 inhibitorsSodium-glucose cotransporter 2 inhibitor useOptum Labs Data WarehouseProportion of patientsSGLT2 inhibitor usePresence of diabetesRecurrent cardiovascular eventsAtherosclerotic cardiovascular diseaseCotransporter 2Analysis of U.S. dataSevere albuminuriaPrescription patternsCardiovascular eventsCommercial insuranceEffect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose‐lowering therapy: A pre‐specified analysis of the DELIVER trial
Lassen M, Ostrominski J, Inzucchi S, Claggett B, Kulac I, Jhund P, de Boer R, Hernandez A, Kosiborod M, Lam C, Martinez F, Shah S, Desai A, Petersson M, Langkilde A, Docherty K, McMurray J, Solomon S, Vaduganathan M. Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose‐lowering therapy: A pre‐specified analysis of the DELIVER trial. European Journal Of Heart Failure 2024, 26: 1539-1548. PMID: 38745498, DOI: 10.1002/ejhf.3269.Peer-Reviewed Original ResearchConceptsBackground glucose-lowering therapyLeft ventricular ejection fractionGlucose-lowering therapySodium-glucose cotransporter 2 inhibitorsHeart failureClinical outcomesComposite of worsening HFPrimary outcomeInsulin useBenefits of dapagliflozinVentricular ejection fractionEffects of dapagliflozinType 2 diabetesEjection fractionRandomized patientsMetformin useConcomitant metforminCardiovascular deathFollow-upContemporary guidelinesDapagliflozinTreatment effectsDELIVER trialTreatment benefitT2DPrognostic Models for Mortality and Morbidity in Heart Failure With Preserved Ejection Fraction
McDowell K, Kondo T, Talebi A, Teh K, Bachus E, de Boer R, Campbell R, Claggett B, Desai A, Docherty K, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Simpson J, Vaduganathan M, Jhund P, Solomon S, McMurray J. Prognostic Models for Mortality and Morbidity in Heart Failure With Preserved Ejection Fraction. JAMA Cardiology 2024, 9: 457-465. PMID: 38536153, PMCID: PMC10974691, DOI: 10.1001/jamacardio.2024.0284.Peer-Reviewed Original ResearchConceptsNT-proBNP levelsHF hospitalizationHeart failureCardiovascular deathNT-proBNPPARAGON-HFClinical outcomesN-terminal pro-brain natriuretic peptideAngiotensin receptor-neprilysin inhibitionComposite of HF hospitalizationSodium-glucose cotransporter 2 inhibitorsHigh-sensitivity cardiac troponin TMeta-Analysis Global GroupPro-brain natriuretic peptidePARAGON-HF trialBiomarker-driven approachesRisk of cardiovascular deathHigh-risk patientsInformed care decisionsCardiac troponin TPredictive of all-causePredictive of morbidityTransient ischemic attack/strokeChronic obstructive pulmonary diseaseObstructive pulmonary diseaseEffectiveness of glucose-lowering medications on cardiovascular outcomes in patients with type 2 diabetes at moderate cardiovascular risk
McCoy R, Herrin J, Swarna K, Deng Y, Kent D, Ross J, Umpierrez G, Galindo R, Crown W, Borah B, Montori V, Brito J, Neumiller J, Mickelson M, Polley E. Effectiveness of glucose-lowering medications on cardiovascular outcomes in patients with type 2 diabetes at moderate cardiovascular risk. Nature Cardiovascular Research 2024, 3: 431-440. PMID: 38846711, PMCID: PMC11156225, DOI: 10.1038/s44161-024-00453-9.Peer-Reviewed Original ResearchAdverse cardiovascular eventsGlucose-lowering medicationsType 2 diabetesCardiovascular diseaseGLP-1RACardiovascular eventsGlucagon-like peptide-1 receptor agonistsSodium-glucose cotransporter 2 inhibitorsPeptide-1 receptor agonistsDipeptidyl peptidase-4 inhibitorsPeptidase-4 inhibitorsRetrospective cohort studyCardiovascular disease risk reductionGlucose-lowering agentsModerate cardiovascular riskCardiovascular risk reductionReceptor agonistsEffects of glucose-lowering medicationsRisk reductionCardiovascular riskCohort studyCardiovascular outcomesHigh riskBaseline riskModerate riskDapagliflozin in patients with heart failure and previous myocardial infarction: A participant‐level pooled analysis of DAPA‐HF and DELIVER
Peikert A, Vaduganathan M, Claggett B, Kulac I, Foà A, Desai A, Jhund P, Carberry J, Lam C, Kosiborod M, Inzucchi S, Martinez F, de Boer R, Hernandez A, Shah S, Køber L, Ponikowski P, Sabatine M, Petersson M, Langkilde A, McMurray J, Solomon S. Dapagliflozin in patients with heart failure and previous myocardial infarction: A participant‐level pooled analysis of DAPA‐HF and DELIVER. European Journal Of Heart Failure 2024, 26: 912-924. PMID: 38487939, DOI: 10.1002/ejhf.3184.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionHeart failureHistory of MIMyocardial infarctionPrimary outcomeDAPA-HFWorsening HFSpectrum of left ventricular ejection fractionLeft ventricular ejection fraction spectrumCardiovascular deathSodium-glucose cotransporter 2 inhibitorsRisk of disease progressionComposite of cardiovascular deathRisk of adverse cardiovascular outcomesIncreased risk of adverse cardiovascular outcomesRisk of cardiovascular deathVentricular ejection fractionHistory of myocardial infarctionSerious adverse eventsAdverse cardiovascular outcomesSymptomatic HFEjection fractionAdverse eventsCovariate-adjusted modelsPooled analysisDecline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Mc Causland F, Claggett B, Vaduganathan M, Desai A, Jhund P, Vardeny O, Fang J, de Boer R, Docherty K, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Saraiva J, McGrath M, Shah S, Verma S, Langkilde A, Petersson M, McMurray J, Solomon S. Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JAMA Cardiology 2024, 9: 144-152. PMID: 37952176, PMCID: PMC10641768, DOI: 10.1001/jamacardio.2023.4664.Peer-Reviewed Original ResearchSodium-glucose cotransporter 2 inhibitorsEGFR declineGlomerular filtration rateEjection fractionHeart failurePrespecified analysisFiltration rateMonths 1Estimated glomerular filtration rateDapagliflozin-treated patientsKidney composite outcomePrimary cardiovascular outcomeHeart Failure TrialChronic kidney diseaseCotransporter 2 inhibitorsInternational multicenter studyLives of patientsBaseline eGFRKidney eventsKidney outcomesCardiovascular outcomesComposite outcomePrognostic factorsFailure TrialMulticenter study
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply